ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
CSL Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CSL112 to Assess Reduction of Early Recurrent Cardiovascular Events in Heart Attack Survivors
March 26, 2018CSL Behring, a global biotherapeutics leader, today announced the initiation of the AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes II) clinical trial and the first patient enrollment. -
Russian researchers develop a rapid diagnostic test for heart attack
February 01, 2018The team has managed to combine qualitative and quantitative immunochromatographic test principles in a simple and effective bioanalytical system -
Women at risk from sub-standard heart attack care
January 09, 2018New research part funded by the British Heart Foundation has highlighted stark inequalities between the treatment of men and women with heart attack and the effect this is having on survival.
Pharma Sources Insight January 2025
